Blood Cancer Drug Cuts Death Risk in Clinical Trial, Maker Says

Blood Cancer Drug Cuts Death Risk in Clinical Trial, Maker Says
AI-generated illustration

Sellas Life Sciences says its experimental immunotherapy reduced the risk of death in a blood cancer trial, though full results have not yet been published.

Sellas Life Sciences has announced that its experimental immunotherapy drug showed a reduced risk of death among patients with blood cancer in a clinical trial. The claim was posted by the company and reported by the medical news outlet STAT News.

The drug is an immunotherapy — a treatment that works by prompting the body’s own immune system to target and attack cancer cells rather than using chemotherapy or radiation directly. Blood cancers include conditions such as leukaemia, lymphoma, and myeloma, which affect the blood, bone marrow, and lymphatic system.

No full trial data has been published at this stage. The announcement appears to be based on top-line results — early headline figures released before a complete peer-reviewed paper is available. That means the findings have not yet been independently scrutinised by other scientists.

Clinical trial results, even promising ones, can change once full data is examined. Regulatory approval from bodies such as the Medicines and Healthcare products Regulatory Agency (MHRA) in the UK would be required before any such treatment could be offered to NHS patients.

Anyone concerned about symptoms of blood cancer — which can include unexplained tiredness, night sweats, frequent infections, unusual bruising, or swollen glands — should contact their GP or call NHS 111.

Key information

  • GP or NHS 111 — for anyone with concerns about blood cancer symptoms
  • Blood Cancer UK helpline — 0808 2080 888, open Monday to Friday
  • Macmillan Cancer Support — 0808 808 00 00, available 7 days a week, 8am to 8pm
  • NHS 111 — call 111 or go online for non-emergency health advice

Source: @statnews